VectorBuilder Powers FDA IND Approval of World’s First Umbilical Cord Blood-Derived Allogeneic CAR-T Product
VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy ...
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
Best-in-Class Design to Enhance Therapeutic Benefit and Expand Treatment Potential Across a Range of Autoimmune Disease Indications; Inno ...
CARsgen's Allogeneic CD38 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...
Targeted Oncology7d
First Dose of CD38-Targeting CAR T-Cell Therapy Administered in AML
The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy ...
Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer
As CTO, Mr. Beneski will oversee Allogene’s technical operations, leveraging his extensive expertise in biologics manufacturing, process development, and operational leadership to carry on the work of ...
Medindia10d
CARsgen's Allogeneic CD38 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial
THANK (Target to Hinder the Attack of NK cells)-uCAR® is CARsgen's proprietary technology to generate allogeneic CAR-T cells with improved expansion and persistence by modifying donor-derived T ...
Allogene Therapeutics, Inc.: Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...
Pharmabiz8d
CARsgen’s allogeneic CD38 CAR-T therapy administers first dose in an investigator-initiated trial
CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumours, announces that KJ-C2320, an allogeneic CAR ...